Description
Matrix GLa protein inhibits vascular calcification in a vitamin K-dependent manner. Serum levels of this peptide may be used as a biomarker for renal failure, diabetes, and cardiovascular events.
| Product Unit Size | Cost | Quantity | Stock |
|---|
Matrix GLa protein inhibits vascular calcification in a vitamin K-dependent manner. Serum levels of this peptide may be used as a biomarker for renal failure, diabetes, and cardiovascular events.
| Purity | ≥95% |
|---|---|
| Formula | C18H25N5O5S |
| Formula Wt. | 423.4 |
| Synonym | MGP-pNa |
| Solubility | Soluble in water. |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
McCarty MF, DiNicolantonio JJ. The molecular biology and pathophysiology of vascular calcification. Postgrad Med. 2014 Mar;126(2):54-64. PMID: 24685968.
Schurgers LJ, Uitto J, Reutelingsperger CP. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol Med. 2013 Apr;19(4):217-26. PMID: 23375872.
Mycotoxin that has structural similarity to est...
Enalapril metabolite; ACE inhibitor.
Alkaloid originally found in species of Aconitu...
ACE inhibitor.
Isoflavone found in soy; SERM.
Trichothecene mycotoxin produced by Fusarium; p...
Peptide, involved in synapse formation and cell...
Statin; HMG-CoA reductase inhibitor, potential ...
ITC, erucin analog.
Aminoglycoside; protein translation inhibitor.<...
HDAC1/2/3/11 inhibitor.
principal metabolic product of COX-2
Endogenous peptide, involved in paracrine and a...
Aromatase inhibitor.
T-type calcium channel blocker
CDK inhibitor, L-type Ca2+ channel blocker.
Allosteric inhibitor
Peptide, derivative of AT III, cleavage product...
Synthetic peptide; FPRL1 agonist.
Loop diuretic; NKCC symporter and HSP90 inhibit...